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Summary
Background In the PATHWAY-2 study of resistant hypertension, spironolactone reduced blood pressure substantially 
more than conventional antihypertensive drugs. We did three substudies to assess the mechanisms underlying this 
superiority and the pathogenesis of resistant hypertension.
Methods PATHWAY-2 was a randomised, double-blind crossover trial done at 14 UK primary and secondary care sites 
in 314 patients with resistant hypertension. Patients were given 12 weeks of once daily treatment with each of placebo, 
spironolactone 25–50 mg, bisoprolol 5–10 mg, and doxazosin 4–8 mg and the change in home systolic blood pressure 
was assessed as the primary outcome. In our three substudies, we assessed plasma aldosterone, renin, and 
aldosterone-to-renin ratio (ARR) as predictors of home systolic blood pressure, and estimated prevalence of primary 
aldosteronism (substudy 1); assessed the effects of each drug in terms of thoracic fluid index, cardiac index, stroke 
index, and systemic vascular resistance at seven sites with haemodynamic monitoring facilities (substudy 2); and 
assessed the effect of amiloride 10–20 mg once daily on clinic systolic blood pressure during an optional 6–12 week 
open-label runout phase (substudy 3). The PATHWAY-2 trial is registered with EudraCT, number 2008–007149–30, 
and ClinicalTrials.gov, number NCT02369081.
Findings Of the 314 patients in PATHWAY-2, 269 participated in one or more of the three substudies: 126 in substudy 1, 
226 in substudy 2, and 146 in substudy 3. Home systolic blood pressure reduction by spironolactone was predicted by 
ARR (r²=0·13, p<0·0001) and plasma renin (r²=0·11, p=0·00024). 42 patients had low renin concentrations (predefined 
as the lowest tertile of plasma renin), of which 31 had a plasma aldosterone concentration greater than the mean value 
for all 126 patients (250 pmol/L). Thus, 31 (25% [95% CI 17–33]) of 126 patients were deemed to have inappropriately 
high aldosterone concentrations. Thoracic fluid content was reduced by 6·8% from baseline (95% CI 4·0 to 8·8; 
p<0·0001) with spironolactone, but not other treatments. Amiloride (10 mg once daily) reduced clinic systolic blood 
pressure by 20·4 mm Hg (95% CI 18·3–22·5), compared with a reduction of 18·3 mm Hg (16·2–20·5) with 
spironolactone (25 mg once daily). No serious adverse events were recorded, and adverse symptoms were not 
systematically recorded after the end of the double-blind treatment. Mean plasma potassium concentrations increased 
from 4·02 mmol/L (95% CI 3·95–4·08) on placebo to 4·50 (4·44–4·57) on amiloride (p<0·0001).
Interpretation Our results suggest that resistant hypertension is commonly a salt-retaining state, most likely due to 
inappropriate aldosterone secretion. Mineralocorticoid receptor blockade by spironolactone overcomes the salt 
retention and resistance of hypertension to treatment. Amiloride seems to be as effective an antihypertensive as 
spironolactone, offering a substitute treatment for resistant hypertension.
Funding British Heart Foundation and UK National Institute for Health Research.
Copyright © 2018 The Author(s). Published by Elsevier Ltd. This is an Open Access article under the CC BY 4.0 license.
Introduction
Resistant hypertension is defined as a blood pressure that 
is uncontrolled despite treatment with at least three blood 
pressure-lowering drugs, including a diuretic, usually also 
including an angiotensin-converting enzyme (ACE) 
inhibitor or angiotensin receptor blocker (ARB) and a 
calcium channel blocker (CCB), and after exclusion of 
treatable secondary causes of hypertension.1 Resistant 
hypertension affects up to 10% of patients treated for 
hypertension and is associated with a high risk of 
cardiovascular morbidity and mortality.2 In the random-
ised, placebo-controlled crossover trial PATHWAY-2,3 we 
tested the recommendation4 to treat resistant hyper-
tension by addition of a drug that blocks either the mineral-
ocorticoid or adrenergic receptors. In PATHWAY-2, the 
mineral ocorticoid receptor antagonist spironolactone 
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(25–50 mg per day) was more effective at lowering blood 
pressure than bisoprolol (5–20 mg daily), doxazosin 
(4–8 mg daily), or placebo.3 This finding is supported by 
evidence from observational studies.5
Understanding the mechanism of the blood pressure-
lowering superiority of spironolactone in resistant 
hypertension would help to delineate the patho-
physiological basis of resistant hypertension and provide a 
rationale for developing alternative treatment strategies for 
patients in whom spironolactone is poorly tolerated. The 
hypothesis underpinning PATHWAY-2 was that resistant 
hypertension is predominantly a sodium-retaining state 
(despite background treatment with thiazide-type 
diuretics) and that further diuretic (more correctly, 
natriuretic) treatment would be the most effective means 
of lowering blood pressure.3 PATHWAY-2 incorporated a 
series of prespecified hormonal and haemodynamic 
measurements designed to facilitate investigation of the 
pathophysiology of resistant hyper tension and its drug 
treatment.6 We now report the results of these analyses, 
which address three clinically important questions.
First, what is the relation between baseline plasma 
renin, aldosterone, and the aldosterone-to-renin ratio 
(ARR) and the blood pressure-lowering response to 
spironolactone, bisoprolol, doxazosin, and placebo? Con-
sistent with our hypothesis that resistant hypertension is 
See Online for appendix
Research in context
Evidence before this study
We previously reported the results of the PATHWAY-2 
randomised controlled trial, which showed that low-dose 
spironolactone (25–50 mg daily), when added to standard blood 
pressure-lowering drugs, was substantially more effective at 
lowering blood pressure in patients with resistant hypertension 
than placebo or alternative blood pressure-lowering drugs 
(bisoprolol or doxazosin). On Sept 17, 2017, we searched 
MEDLINE, Embase, and the Cochrane Central Register of 
Controlled Trials using the search terms “resistant hypertension”, 
“pathophysiology”, “mechanisms”, “amiloride”, 
“hemodynamics”, and “aldosterone” for reports in English 
published up to July 31, 2017. Our search strategy included 
reports of randomised controlled trials as well as open and 
observational studies of drug treatment of resistant 
hypertension that included any data analysing mechanisms and 
pathophysiology of resistant hypertension or the use of 
amiloride. The available evidence was scarce. Findings from two 
observational studies had suggested that plasma renin 
concentrations were often more suppressed than anticipated in 
patients with resistant hypertension, consistent with this being a 
sodium-retaining and volume-expanded state. In another study, 
non-invasive haemodynamic measurements via impedance 
cardiography were used to establish whether treatment adjusted 
on the basis of haemodynamic characteristics would be more 
effective than empirical treatment at lowering blood pressure in 
resistant hypertension, but the findings were inconclusive. In a 
prospective study of 88 consecutive patients referred to a 
university clinic for resistant hypertension, researchers reported 
that 18 (20%) had increased urinary aldosterone and suppressed 
plasma renin concentrations, despite salt intake in excess of 
200 mmol/24 h. Background treatment, including β-blockade, 
was not discontinued. Authors of other observational studies 
and commentaries have speculated that many cases of resistant 
hypertension might result from undetected 
aldosterone-producing adenomas. Results of many studies have 
shown the efficacy of low-dose (2·5–5·0 mg) amiloride added to 
thiazide, including reduction of morbidity and mortality. We 
have previously reported the efficacy of high-dose (10–40 mg) 
amiloride in treated hypertension, but amiloride has not 
previously been compared with spironolactone or other drugs in 
patients with resistant hypertension.
Added value of this study
In the PATHWAY-2 trial, spironolactone reduced blood 
pressure substantially more than conventional 
antihypertensive drugs in patients with resistant 
hypertension. In order for the results of PATHWAY-2 to 
change practice, it was important to show a mechanistic basis 
underpinning the superiority of spironolactone. The results of 
the PATHWAY-2 mechanisms substudies show that the 
efficacy of spironolactone as an antihypertensive drug could 
be anticipated from our findings that resistant hypertension 
is a salt-retaining condition, associated with high 
aldosterone-to-renin ratios, and that spironolactone was 
substantially superior to the other standard antihypertensive 
drugs in reducing indices of salt and water retention—
ie, it was reducing blood pressure primarily via diuretic 
actions. Physicians who are hesitant to prescribe 
spironolactone for hypertension, either because it is not a 
universally licensed indication, or because of antiandrogen-
related intolerance, will be reassured by our additional finding 
that amiloride 10–20 mg achieved similar reductions in blood 
pressure as spironolactone, with similar, slight changes in 
electrolytes.
Implications of all the available evidence
We propose that spironolactone, or amiloride if spironolactone 
is not tolerated, should be first-line treatment for resistant 
hypertension, in addition to background treatment with an 
angiotensin-converting enzyme inhibitor or angiotensin 
receptor blocker, a calcium channel blocker, and a diuretic, in 
patients with an eGFR greater than 45 mL/min/1·73m² and 
serum potassium within the normal range. Among this cohort 
are likely to be some —perhaps many—patients whose 
hypertension is caused by primary aldosteronism. We 
encourage a reconsideration of which diagnostic thresholds for 
primary aldosteronism are appropriate in patients with 
resistant hypertension, to facilitate recognition of a potentially 
curable aldosterone-producing adenomas in patients with 
resistant hypertension.
London, UK (Prof M J Caulfield, 
J Salsbury, Prof M J Brown)
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predominantly a sodium-retaining state, we expected 
plasma renin to be relatively suppressed despite back-
ground treatment with an ACE inhibitor or an ARB, a 
CCB, and a diuretic—ie, the so-called A+C+D treatment 
strategy.3,4 A finding of a suppressed renin concentration, 
despite treatments that usually increase plasma renin, 
would be consistent with resistant hypertension being a 
sodium-retaining state. We also hypothesised that the 
blood pressure-lowering response to spironolactone, but 
not to other drugs, would be greatest in participants with 
the lowest plasma renin concentrations and highest 
ARRs, consistent with sodium retention being largely a 
consequence of auto nomous aldosterone production. The 
proportion of patients exceeding validated thresholds for 
the diagnosis of primary aldosteronism was also assessed.
Second, we aimed to assess the haemodynamic 
responses to the various drug treatments and placebo 
and their effect on cardiac output, systemic vascular 
resistance, and thoracic fluid content, testing the 
hypothesis that the superior action of spironolactone in 
lowering blood pressure in resistant hypertension would 
be consistent with those of a diuretic.
Third, we hypothesised that if the superiority of 
spironolactone in resistant hypertension was due to its 
natriuretic actions, then amiloride would similarly 
decrease blood pressure. Like spironolactone, amiloride 
is a distal tubular diuretic that inhibits the aldosterone-
sensitive epithelial sodium channel. Notably, a low-dose 
thiazide and amiloride combination achieved a greater 
reduction in blood pressure from baseline than high-
dose thiazide alone in patients with hypertension in the 
PATHWAY-3 trial.7
Methods
Study design and participants
PATHWAY-2 was a 12-month, double-blind, placebo-
controlled, randomised, crossover trial done at 12 secondary 
care sites and two primary care sites in the UK, in patients 
aged 18–79 years with systolic blood pressure of at least 
140 mm Hg and home systolic average blood pressure of at 
least 130 mm Hg despite treatment with maximum 
tolerated doses of three blood pressure-lowering drugs 
(ie, A+C+D). Secondary causes of hypertension had been 
excluded and specific procedures were done to confirm 
resistant hypertension and patient adherence to their 
baseline medications.6 In the final year of PATHWAY-2, a 
new mass spectrometric assay permitted a spot urine test 
at baseline and the end of each double-blind phase to be 
checked for background and study drugs.8
The haemodynamics and amiloride runout substudies 
were incorporated within the original protocol of 
PATHWAY-2, and the aldosterone substudy was added 
later. By design, each was done in a subset of patients, 
restricted by either recruitment date (aldosterone 
measurements [substudy 1]), setting (haemodynamic 
measurements [substudy 2]), or preference of the patient 
or doctor (amiloride runout [substudy 3]).3,6 The overall 
design of PATHWAY-2 and its incorporated substudies is 
shown in figure 1. Patients from the intention-to-treat 
population in the main study were included in analysis 
of substudy 1 when measurements of aldosterone and 
renin were available; substudy 2 when measurements 
of haemodynamic parameters were available; and 
substudy 3 when clinic blood pressure readings after 
receiving at least one dose of amiloride were available.
In 2012, roughly halfway through recruitment for 
PATHWAY-2, additional funding permitted the addition 
of plasma aldosterone, and thus ARR, to the baseline 
measurements. The objective of substudy 1 was to 
compare the ability of plasma aldosterone, renin, and 
ARR to predict the blood pressure response to each drug 
and to explore the role of aldosterone in patients with 
resistant hypertension. Thus, patients recruited after 
2012 with available baseline aldosterone measurements 
were included in substudy 1.
Patients were eligible for substudy 2 dependent on 
which location they were recruited from; seven of 
the 12 secondary care sites had the necessary specialist 
equipment. Substudy 2 assessed the effects of 
spironolactone, bisoprolol, and doxazosin treatments on 
thoracic fluid, cardiac index, and systemic vascular 
resistance and whether patients’ most effective drug was 
predicted by increased baseline measurements of the 
parameter most likely to be reduced by that drug.
After the double-blind rotation, patients were offered the 
option of returning to primary care or continuing into an 
open-label runout phase (substudy 3). This opportunity for 
a non-randomised study of an alternative to spironolactone 
arose from the need for a period between each patient’s 
final visit and completion of their electronic record, after 
which their best treatment could be unmasked. In this 
open-label phase, we assessed whether amiloride would 
have similar superiority to the other study drugs as was 
hypothesised for spironolactone, and, if so, whether a 
correlation between responses would support switching 
from spironolactone to amiloride in patients who became 
intolerant of spironolactone.
All study participants provided written informed 
consent as part of consent for the main trial and the 
protocol for these studies was approved by the Cambridge 
South Research Ethics Committee.
Procedures
In the main PATHWAY-2 trial, after a 4-week single-blind 
placebo run-in, patients rotated through four cycles of 
once-daily oral treatment with spironolactone 25–50 mg, 
doxazosin 4–8 mg, bisoprolol 5–10 mg, and placebo, each 
for 12 weeks with forced titration to the higher dose after 
6 weeks. The order in which drugs were administered to 
each patient was randomly assigned via a central computer 
system. Patients and investigators were masked to drug 
treatment groups. Blood was collected at the end of the 
placebo run-in, and batched results did not inform 
eligibility of individual patients for either the main trial or 
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its substudies. Plasma renin was measured in a central 
laboratory as direct renin mass using the LIAISON 
automated chemiluminescent immunoassay (DiaSorin, 
Saluggia, Italy).9 Plasma aldosterone was also measured 
using the LIAISON automated chemiluminescent im-
munoassay10 or by mass spectrometry.
For substudy 2, non-invasive haemodynamic assess-
ments of fluid balance, cardiac performance, and vascular 
resistance were done with the patient supine, at baseline 
and at the end of each treatment cycle, using thoracic 
electrical bioimpedance cardiography (CardioDynamics 
BioZ Impedance Cardiography Hemodynamic Monitor, 
CardioDynamics, San Diego, CA, USA).10 Four pairs of 
electrocardiogram electrodes were applied to the base of 
the neck and the lower thorax at the diaphragm level, and 
a high frequency, low magnitude current was applied. The 
difference between input and sensed voltage is established 
by the impedance of the thorax, which is inversely 
proportional to thoracic fluid volume. Stroke volume is 
calculated from the change of impedance (thoracic fluid 
content) over the cardiac cycle time. Because cardiac 
output and total body fluid volume is related to body mass, 
all blood flow parameters were indexed to body surface 
area in m². Stroke index was calculated as stroke volume 
divided by body surface area (mL per heart beat per m²). 
Cardiac index (cardiac output) was calculated as stroke 
index multiplied by heart rate (L/min/m²). Systemic 
vascular resistance index was then derived from the 
measurements of cardiac index and blood pressure 
(dyn ×   sec/cm⁵/m²). Thoracic fluid content index, an index 
of body fluid volume, is expressed as 1/kΩ/m². Previous 
studies have shown these primary variables to be highly 
reproducible on repeated measures in the same patient, 
separated by days or weeks.10,11
In substudy 3, participating patients received amiloride 
10 mg once daily for 6 weeks, followed by the option to 
up-titrate to 20 mg daily for a further 6 weeks if blood 
pressure remained uncontrolled (figure 1). Seated clinic 
blood pressure was measured after 6 and 12 weeks of 
amiloride treatment.
In the main PATHWAY-2 study, blood pressure was 
measured both as a home blood pressure average and 
seated clinic blood pressure. For substudy 1 examining the 
relations between hormones and the blood pressure 
response to treatment, home systolic blood pressure 
measurements were used. Home blood pressure was a 
single mean of 24 seated home blood pressure readings 
recorded in the morning and evening for 4 consecutive 
days, with triplicate readings at each measurement 
session. Home blood pressure was recorded over the 
4 days before the baseline visit at the end of placebo run-in, 
and before the 6-week and 12-week visits of each double-
blind treatment cycle. If incomplete, a minimum of 
six of the 24 possible blood pressure recordings over 4 days 
was required, or patients were excluded from the analysis. 
Home blood pressure was not recorded during the 
open-label amiloride runout phase. Thus in substudy 3, 
the clinic blood pressure-lowering effect of amiloride was 
compared with clinic blood pressure reduction on other 
active treatments or placebo. Clinic blood pressure was 
the average of the last two of the triplicate readings 
recorded at the 6-weekly study visits during both the 
double-blind treatment cycles and the open-label 
amiloride runout. Visits could be morning or afternoon, 
Placebo once per day for 
12 weeks
Amiloride open-label
12-week run-out
(10–20 mg once per day)
Screening for resistant hypertension
Treatment A+C+D
Directly observed therapy to exclude 
non-compliance
Home blood pressure measurement to 
exclude white coat hypertension
Secondary hypertension excluded
Doxazosin 4–8 mg once 
per day for 12 weeks
Home systolic blood 
pressure measured at
6 and 12 weeks
Spironolactone 25–50 mg 
once per day for 12 weeks
Haemodynamic assessments at
baseline and at 6 weeks and
12 weeks of each treatment cycle
Bisoprolol 5–10 mg once 
per day for 12 weeks
Plasma renin, aldosterone, 
and aldosterone-to-renin 
ratio
Group assignment
Baseline
4-week single-blind
placebo run-in
(treated with A+C+D)
Figure 1: PATHWAY 2 study design
Stages in the crossover trial at which measurements for the three mechanistic substudies were taken. Green shows substudy 1, blue shows substudy 2, and pink shows 
substudy 3. During the 12-week drug cycles, the lower dose was given for the first 6 weeks, then the higher dose was given for the second 6 weeks. No washout period 
was used between cycles. The figure shows one of the 24 possible passages through the drug cycles, the order of which was randomly assigned within blocks of 24 
patients. A+C+D=an angiotensin-converting enzyme inhibitor or angiotensin receptor blocker, a calcium channel blocker, and a diuretic.
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but were at a consistent time of day for each patient. The 
home and clinic blood pressures were measured by a 
WatchBP Home monitor (Microlife, Clearwater, FL, USA), 
allocated to the patient for the year of double-blind 
treatment.
Outcomes
The prespecified objectives and outcome measures for 
these mechanistic substudies of the PATHWAY-2 trial 
were to define the relations between baseline plasma 
renin, aldosterone, and ARR (on background treatment 
with A+C+D) and the blood pressure response to 
spironolactone, doxazosin, bisoprolol, and placebo; to 
analyse the haemodynamic response to the blood 
pressure-lowering treatments in resistant hypertension 
to establish their most likely mechanism of action; and to 
use the open-label runout phase of the study to establish 
whether amiloride would achieve blood pressure 
reductions similar to spironolactone in patients with 
resistant hypertension. Exploratory analyses of the 
prevalence of primary aldosteronism were also done. 
Only serious adverse events were recorded during the 
open-label amiloride runout.
In the aldosterone substudy (substudy 1) of patients who 
had a baseline measurement of ARR, the main outcomes 
were the baseline measurement of ARR, and the 
regression upon this of the change from baseline in home 
systolic blood pressure averaged (mean) across the 6-week 
and 12-week visits of each double-blind treatment. In the 
haemodynamic substudy (substudy 2) of patients at the 
seven sites that had a CardioDynamics BioZ Impedance 
Cardiography Hemodynamic Monitor (SonoSite, San 
Diego, CA USA), the main outcomes were the changes in 
thoracic fluid index, cardiac index, stroke index, and 
systemic vascular resistance between baseline and the end 
of each double-blind treatment. In the amiloride substudy 
(substudy 3) of patients who continued after the double-
blind treatment cycles into an optional open-label runout 
on amiloride, the main outcome was change in clinic 
systolic blood pressure between baseline and end of 
6 weeks (low-dose) or 12 weeks (high-dose) of amiloride 
treatment. In all substudies, treatment refers to the study 
drug administered in addition to the background 
treatment with A+C+D (an ACE inhibitor or an ARB, a 
CCB, and a diuretic).
Statistical analysis
This PATHWAY-2 mechanisms study is a series 
of prespecified substudies embedded within the 
PATHWAY-2 trial.6 The sample size and statistical power 
calculations were done for the primary outcome of the 
PATHWAY-2 trial and do not apply to these substudies.
In substudy 1, we used regression analyses to explore 
the relation between each of baseline plasma renin, 
aldosterone, and the ARR and blood pressure responses 
to the active treatments and placebo. Exploratory analyses 
were post hoc, but when appropriate followed the 
prespecified PATHWAY definition of high and low renin 
concentrations being those within the upper and lower 
tertiles of the plasma renin distribution. The prevalence 
of primary aldosteronism was estimated using the 
threshold of 60·94 for ARR in the post-captopril 
suppression test, and a threshold of 5·3 (mmol L–¹)–¹ 
for the SUSPPUP ratio ([serum sodium/urinary 
sodium])/([serum potassium²/urinary potassium]).12,13 In 
substudy 2, for analysis of haemodynamic responses to 
drug treatment, and to assess them as predictors of blood 
pressure response, we used mixed-effects models with 
an unstructured covariance matrix for repeat observations 
in the same patient. In substudy 3, we also used mixed 
models for blood pressure response to amiloride versus 
other active treatments or placebo.
Substudy 1: plasma aldosterone, 
renin, and aldosterone-to-renin 
ratio (n=126) 
PATHWAY-2 trial (n=314)
77
Substudy 2: haemodynamic 
analyses (n=226) 
 
Substudy 3: amiloride study
(n=146) 
61
48
40
13
22
8
Overlap of patients participating 
in the PATHWAY-2 mechanisms 
substudies
Aldosterone
Haemodynamics
Amiloride
Figure 2: Participant numbers and measurements in the PATHWAY-2 
mechanisms substudies
Substudies Main trial 
(n=314)
Aldosterone 
(n=126)
Haemodynamics 
(n=226)
Amiloride 
(n=146)
Age, years 60·3 (9·6) 61·1 (9·5) 59·6 (10·1) 61·2 (9·6)
Men 86 (70%) 159 (70%) 109 (75%) 217 (69%)
Women 40 (30%) 67 (30%) 37 (25%) 97 (31%)
Bodyweight, kg 94·1 (17·6) 94·9 (19·0) 96·9 (20·3) 93·9 (18·3)
Systolic blood pressure, mm Hg 159·0 (14·3) 156·7 (14·2) 158·0 (14·0) 157·4 (14·3)
Diastolic blood pressure, mm Hg 92·4 (11·4) 89·9 (11·7) 91·0 (11·3) 90·3 (11·5)
Heart rate, beats per min 77·0 (12·3) 77·5 (11·9) 77·8 (11·1) 77·3 (12·2)
24 h urine Na+, mmol 151·6 (74·7) 148·5 (73·5) 153·0 (73·5) 138·1 (71·7)
24 h urine K+, mmol 79·0 (27·4) 72·5 (28·3) 77·4 (29·6) 70·8 (29·7)
Plasma Na+, mmol/L 139·2 (3·2) 139·7 (3·1) 140·1 (2·8) 139·6 (3·0)
Plasma K+, mmol/L 4·07 (0·44) 4·08 (0·46) 4·02 (0·41) 4·08 (0·44)
eGFR, mL/min/1·73m² 97·4 (26·6) 93·1 (26·6) 97·6 (25·5) 91·6 (26·8)
Diabetes 12 (10%) 39 (17%) 22 (15%) 43 (14%)
Renin, mU/L 33 (14·0–77·0) 33 (13·5–71·5) 34 (14·0–92·0) 34 (14·0–95·0)
Aldosterone, pmol/L 262 (179–352) 247 (178–343) 270 (187–353) 262 (179–352)
Data are mean (SD), n (%), or median (IQR). eGFR=estimated glomerular filtration rate.
Table: Baseline characteristics of patients in the PATHWAY-2 trial and the PATHWAY-2 mechanisms 
substudies
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In the mixed models, patients were defined as random 
effects, with no structure imposed on the within-subject 
covariance matrix, and all other covariates were regarded 
as fixed. Analyses were done with SAS, version 9.3 (Cary, 
NC, USA). Data checking for compliance with protocol 
were done by the Robertson Centre for Biostatistics, 
University of Glasgow (UK). The PATHWAY-2 trial is 
registered with EudraCT, number 2008–007149–30, and 
ClinicalTrials.gov, number NCT02369081.
Role of the funding source
The funders of the study had no role in study design, data 
collection, data analysis, data interpretation, or the writing 
of the report. The investigators and all authors had sole 
discretion in the data analysis, interpretation, writing of 
the report, and the decision to submit for publication. 
The corresponding author had full access to all of the data 
and the final responsibility to submit for publication.
Results
Between May 15, 2009, and July 8, 2014, we screened 
436 patients for the PATHWAY-2 study. 335 were randomly 
assigned to treatment groups, of whom 21 had no follow-
up for any drug and were excluded from the intention-to-
treat analysis, which comprised 314 patients. Of these, 
126 patients had baseline measurements of aldosterone 
and ARR, 226 participated in the haemo dynamic analyses 
with impedance cardiography, and 146 participated in the 
amiloride runout phase of the study (figure 2).
The baseline characteristics of the patients in the 
three substudies and the overall trial population were 
similar (table). The mean baseline clinic blood pressure 
in the overall trial population was 157·4/90·3 mm Hg 
(SD 14·3/11·5); baseline electrolytes and estimated 
glomerular filtration rate (eGFR) were normal; and 24-h 
urinary sodium concentrations were about 150 mmol 
(equivalent to a salt intake of 9 g per day).
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Figure 3: Correlations of plasma aldosterone, renin, and ARR, with blood pressure response to spironolactone averaged (mean) across the 6-week and 
12-week visits of each treatment cycle
(A) Relation between baseline plasma renin, aldosterone, and the ARR and the home systolic blood pressure response to spironolactone. (B) Best-fit relation between 
plasma aldosterone and renin concentrations at baseline. Regression equations for change in systolic blood pressure (y): y=(–25·20)+6·86 × (log10renin), r²=0·116 
(proportion of variance accounted for by the model); y=8·92–9·85 × (log10aldosterone), r²=0·034; and y=(–8·87)–6·87 × (log10ARR), r²=0·138. Regression equation for 
aldosterone vs renin: log10aldosterone=2·60–0·279 × (log10renin) + 0·081 × (log10renin)², r²=0·043. ARR=aldosterone-to-renin ratio.
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In substudy 1, the blood pressure-lowering response to 
spironolactone was predicted, in order of significance, by 
baseline ARR (r²=0·13, p<0·0001), by plasma renin 
(r²=0·11, p=0·00024; greatest in patients whose plasma 
renin was suppressed), and weakly by plasma aldosterone 
alone (r²=0·025, p=0·052; figure 3A). No evident asso-
ciations were identified between baseline plasma renin, 
aldosterone, or the ARR and the blood pressure response 
to placebo, doxazosin, or bisoprolol (appendix).
Aldosterone and renin concentrations were not linearly 
correlated (r²=0·0026, slope –0·019 [SE 0·032]). The best 
fit was quadratic (r²=0·043, p=0·060; figure 3B). 42 
patients were in the lowest tertile of plasma renin 
concentration (renin <19 mU/L), of which 31 had a plasma 
aldosterone concentration greater than the mean for all 
126 patients (250 pmol/L). Thus, a prevalence of 31 (25% 
[95% CI 17–33]) of 126 patients was inferred for 
inappropriately high aldosterone concen trations (ie, 
higher than average aldosterone in association with low 
plasma renin). Of the 42 patients in the highest tertile 
(renin >55 mU/L), 20 had a plasma aldosterone 
concentration greater than the mean. A post-hoc analysis 
by sex showed a significant quadratic association between 
aldosterone and renin concen trations in men (r²=0·090, 
p=0·016), but not in women (r²=0·005, p=0·87; appendix). 
Further exploration of the prevalence of primary 
aldosteronism in this cohort was prompted by the paucity 
of datapoints in the left lower quadrants of the graphs 
(figure 3B; appendix), together with the superiority of 
spirono lactone versus conven tional antihypertensive 
drugs in achieving target blood pressure in the main study 
and the prediction of blood pressure response by ARR. 
Lower and upper estimates for prevalence were reached 
using two published criteria. 13 (10% [95% CI 6–17]) of 126 
patients, all of whom were receiving maximum tolerated 
doses of ACE inhibitor or ARB, had an ARR greater than 
60·94 pmol/L–¹ per mU/L, the recently validated threshold 
for post-captopril suppression.12 A less conservative 
estimate was obtained using the SUSPPUP index of 
sodium and potassium clearance: 48 (38%, 95% CI 33–43) 
of 126 patients had a value greater than 5·3 (mmol L–¹)–¹.13 
Similar to ARR, SUSPPUP predicted home systolic blood 
pressure response to spironolactone, but not to the other 
trial drugs (appendix).
In substudy 2, the changes in cardiac output, systemic 
vascular resistance, and thoracic fluid volume from 
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Figure 4: Change in haemodynamic parameters from baseline after 12 weeks treatment with spironolactone, doxazosin, bisoprolol, and placebo
Stroke index, cardiac index, vascular resistance index, and thoracic fluid index were measured at baseline and the end of each double-blind treatment cycle. Least 
squares means adjusted for gender, height, weight, smoking history, baseline systolic blood pressure, and the baseline measurement of the outcome, from a mixed 
model allowing for correlations between repeat measurements in each patient. Coloured bars show least squares mean values and black bars show 95% CIs.
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baseline to the end of the 12-week treatment cycle with 
each treatment were assessed (figure 4). Spironolactone 
significantly reduced thoracic fluid index by about 6·8% 
(95% CI 4·0 to 8·8), with a change of –1·0 1/kΩ/m² 
(95% CI –1·3 to –0·6; p<0·0001). Thoracic fluid index 
was significantly increased by 0·57 1/kΩ/m² with 
doxazosin compared with placebo (95% CI 0·26 to 0·89; 
p=0·00035; figure 4; appendix). Changes in thoracic 
fluid were associated with similar changes in bodyweight 
(appendix). Bisoprolol reduced cardiac index by 
0·17 L/min/m² (0·07–0·28; p=0·0018) and increased 
stroke volume index by 6·5 mL per heart beat per m² 
(4·9–8·2; p<0·0001), reflecting a reduction in heart rate. 
Vascular resistance index showed a small but significant 
reduction with all treatments, including placebo, with 
no apparent differences between treat ments (p=0·066). 
Baseline haemo dynamic characteristics did not predict 
the blood pressure response to treatment (appendix).
In the 144 patients who entered the amiloride runout 
phase (substudy 3), clinic blood pressure after 6 weeks 
was similar to the patients’ previous measurements on 
spironolactone, and much lower than those on either 
placebo or the other two active treatments (p<0·0001; 
figure 5). The reductions in clinic systolic blood pressure 
from baseline to 6 weeks were 20·4 mm Hg (95% CI 
18·3–22·5) with 10 mg amiloride and 18·3 mm Hg 
(16·2–20·5) with 25 mg spironolactone (appendix). The 
superiority of amiloride over other drugs and placebo 
was similar to that reported for spironolactone for all 
patients in the main trial. During the runout phase, no 
forced up-titration was done. In 47 patients whose blood 
pressure remained uncontrolled after 6 weeks of 
treatment with amiloride 10 mg daily and so were given 
20 mg for the second 6 weeks, a similar dose-response 
as for spironolactone 25–50 mg was seen (appendix). 
At both doses, a correlation existed between the systolic 
blood pressure-lowering effect of amiloride and 
spironolactone (r²=0·64, p<0·0001; figure 6). No signifi-
cant change in plasma sodium or eGFR occurred with 
either amiloride or spironolactone treatment, but 
plasma potassium concentrations increased from 
4·02 mmol/L (95% CI 3·95–4·08) with placebo to 4·50 
(4·44–4·57) with amiloride and to 4·35 (4·28–4·42) with 
spironolactone (both p<0·0001; appendix). No serious 
adverse events were recorded with either spironolactone 
or amiloride. Other adverse events were not 
systematically recorded during the open-label phase of 
PATHWAY-2. Adverse events recorded during double-
blind treatment with amiloride are published elsewhere.7
Discussion
The results of our three PATHWAY-2 mechanistic 
substudies show that the blood pressure response to 
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Figure 5: Effect of placebo, amiloride, spironolactone, doxazosin, and 
bisoprolol on clinic blood pressure after 6 weeks of treatment
Both amiloride and spironolactone reduced systolic and diastolic blood pressure 
(unadjusted means) versus placebo (p<0·0001) and versus both doxazosin or 
bisoprolol (p<0·0001). The horizontal line at 140 mm Hg shows target clinic 
systolic blood pressure. Coloured bars show mean values and black bars show 
95% CIs. 
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spironolactone in resistant hypertension is predicted by 
ARR and by plasma renin alone, that the superior 
reduction of blood pressure achieved with spironolactone 
is associated with elimination of thoracic volume excess 
rather than vasodilatation, and that amiloride is similarly 
effective as spironolactone in reducing blood pressure in 
patients with resistant hypertension. We also showed 
that 31 (25%) of 126 patients have an inappropriately high 
plasma aldosterone concentration—ie, that is greater 
than the mean for all patients in the substudy despite a 
plasma renin concentration in the lowest tertile.
The PATHWAY-2 study was designed to test the 
hypothesis that resistant hypertension is a salt-retaining 
state, and that the best treatment is additional diuretic.3 
The hypothesis was supported by the primary and 
secondary outcomes of the study. The aldosterone 
antagonist spironolactone was substantially more 
effective at reducing blood pressure than the licensed 
antihypertensive drugs bisoprolol and doxazosin, and the 
reduction in blood pressure with spironolactone was 
predicted by baseline plasma renin concentrations.3 
The study was not designed to establish whether 
the mechanism of diuresis (or choice of diuretic) was 
crucial to the outcome. However, results from the other 
studies from the PATHWAY programme suggested that 
the reduction of blood pressure after addition of 
spironolactone was greater than would have been 
achieved by increasing the dose of thiazide. In particular, 
the findings from PATHWAY-3 showed that doubling the 
dose of hydrochlorothiazide from 25 to 50 mg reduced 
blood pressure by 4 mm Hg less than the combination of 
hydrochlorothiazide 25 mg with amiloride 10 mg in 
patients with hypertension.7
The rationale for the extra measurements or inter-
vention that we report here was to link the pathophysiology 
of resistant hypertension with response to treatment. 
This link became of particular interest when the primary 
outcome showed spironolactone to be substantially 
superior to the alternatives. Although this outcome was 
scarcely a complete surprise, we had not expected 
superiority to be exhibited across almost the entire 
distribution of plasma renin, with the crossover design 
permitting demonstration that only ten (3%) of 
326 patients in PATHWAY-2 had a plasma renin concen-
tration that predicted better blood pressure response to 
α blockade or β blockade than to spirono lactone. It seems 
reasonable now to conclude that resistant hypertension, 
as previously suspected,14 is predominantly a salt-retaining 
state, often caused by primary or secondary aldosteronism.
One of the best measures of sodium balance is plasma 
renin, as shown by the dose-related, several-times 
increases in plasma renin caused by each of the diuretic 
treatments in PATHWAY-3.7 Definition of normal ranges 
for plasma renin is difficult in patients receiving multiple 
antihypertensive drugs—in particular the A+C+D classes 
required for a diagnosis of resistant hypertension, all of 
which increase concentrations of plasma renin.15 However, 
the median plasma renin value of 34 mU/L in PATHWAY-2 
was only three times greater than the median value 
(11 mU/L) in the 605 patients with untreated hyper-
tension in PATHWAY-1, who had similar blood pressure 
values on no treatment.16 Because we can compare the 
same patient’s response to each of a diuretic drug 
(spironolactone; efficacy inversely correlated to renin) and 
RAS-blocking drug (bisoprolol; positively correlated), we 
can establish the point between the bottom and top of the 
renin distribution at which the diuretic is predicted by the 
plasma renin concentration to be less effective than the 
RAS blocker (appendix). In the patients with resistant 
hypertension in PATHWAY-2, this point lies at the 
extreme right of the renin distribution, with all but 3% of 
patients predicted to respond better to diuretic than RAS 
blocker. This finding is in striking contrast to the effects 
seen in the previously untreated patients of PATHWAY-1, 
in whom a crossover comparison of hydro chlorothiazide 
25 mg and losartan 100 mg was done, and the diuretic 
efficacy is predicted by plasma renin concentration to 
exceed that of the RAS blocker in fewer than half the 
patients.16 Notably, the relatively low median plasma renin 
in PATHWAY-2 is not due to impaired renal clearance 
because the eGFR was normal. Nor was it due to excessive 
dietary sodium intake as the 24 h urinary sodium was 
typical of that seen in western Europe.17
Aldosterone secretion is normally suppressed when 
renin is low, unless there is autonomous aldosterone 
production—eg, from an aldosterone-producing adenoma. 
This aldosterone suppression is apparent during acute salt 
loading, in cross-sectional studies of dietary sodium intake, 
in some of the rare monogenic causes of hypertension, 
and in patients whose low-renin hypertension is due to 
derivatives of naturally occurring mineralocorticoids.18–20 
Unsuppressed plasma aldosterone values raise suspicion 
that they are the driver of salt retention. The paucity of 
patients with low plasma aldosterone and low plasma 
renin in our study is consistent with aldosterone having a 
primary role in many patients with resistant hyper-
tension.14,21 However, none of the patients, even one whose 
hypertension was cured by removal of a 7 mm aldosterone-
producing adenoma,22 exhibited the triad of spontaneous 
hypo kalaemia, completely suppressed renin, and plasma 
aldosterone of more than 550 pmol/L that is currently 
required for diagnosis of primary aldosteronism if a 
suppression test (the alternative method of diagnosis) is to 
be avoided.21
The absence of this triad could be anticipated from the 
eligibility criteria for PATHWAY-2. Yet, despite our 
exclusion of patients with known or suspected secondary 
hypertension, even the more conservative of our 
estimates for primary aldosteronism frequency (10%) 
exceeds the prevalence of 99 (5·9%) of 1672 unselected 
patients with hypertension who were recruited from 
primary care (like most patients in PATHWAY-2), and is 
similar to the 126 (11·2%) of 1125 newly diagnosed 
patients referred to specialist clinics.23,24 Our estimate was 
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enabled by the recent prospective comparison of confir-
matory tests for primary aldo steronism, showing that a 
post-captopril ARR greater than 60·94 pmol/L–¹ per 
mU/L–¹ is equivalent to a positive saline suppression test, 
because all patients at entry to PATHWAY-2 were already 
treated with maximum-tolerated doses of RAS blocker. 
At most, nine patients might have been excluded from 
PATHWAY-2 if entry had (implausibly) required two 
ARR estimations in all screened patients and follow-up 
confirmatory tests when ARR was higher than 
60·94 pmol/L–¹ per mU/L–¹.
However, the criteria for suspecting and diagnosing 
primary aldosteronism are likely to miss many of the zona 
glomerulosa subtype of aldosterone-producing adenomas. 
Their responsiveness to angiotensin and frequent gain-of-
function mutations in an L-type calcium channel25,26 imply 
that their aldosterone secretion might be reduced by RAS 
or calcium blockers sufficiently to decrease to less than 
guideline thresholds, but insufficiently to prevent 
increasingly severe and high-risk hypertension. Zona 
glomerulosa-like aldosterone-producing adenomas, unlike 
the classical Conn’s adenoma, are more common in men 
than in women, are often small, and are more likely to 
present as resistant hypertension than a CT finding.25–28 
Our post-hoc finding of sex difference in the aldosterone–
renin association is therefore notable in this context. The 
same is true of unilateral or bilateral hyper plasia, the 
pathological basis on which is increasingly recognised as 
clusters of aldosterone synthase-rich zona glomerulosa 
cells. These clusters have a several-times higher expression 
of adrenocorticotropic hormone receptors than adjacent 
zona glomerulosa, and many clusters have the same 
somatic mutations as are found in zona glomerulosa-like 
adenomas.29
We have therefore reported an analysis independent of 
ARR, which points to a substantially higher upper 
estimate for prevalence of primary aldosteronism in 
patients with resistant hypertension than the 10% 
estimated by ARR. Acute changes in aldosterone 
concentrations can result in dramatic changes in urine 
sodium-to-potassium ratio.30 At a steady state, these are 
less apparent, but they contribute to an index based on 
the SUSPPUP ratio that has only slightly lower accuracy 
than ARR itself in detecting patients with proven primary 
aldosteronism.13 The correlation of blood pressure 
response to spironolactone but not to the other drugs in 
PATHWAY-2 offers some independent support for the 
sodium-to-potassium or SUSPPUP ratio as a diagnostic 
threshold. The 48 (38%) of 126 PATHWAY-2 substudy 
patients who had a ratio greater than the published 
threshold13 of 5·3 (mmol L–¹)–¹ is similar to the proportion 
of unselected patients with hypertension who have an 
apparently normal ARR but develop acute hyper-
aldosteronism on stress (eg, treadmill test) or ultra-low 
dose (30 ng) of adrenocorticotropic hormone.31 In one 
study,32 the SUSPPUP threshold of 5·3 (mmol L–¹)–¹ had 
lower accuracy; however, some variation is unsurprising 
because ARR itself has no single, universally agreed 
threshold.21
What practical role, then, do we now envisage for the 
assessments and interventions reported here? The non-
invasive haemo dynamic measurements were previously 
proposed as a device for selecting the best treatment in 
resistant hypertension.10 However, we did not find the 
measure ments to be useful for prediction, perhaps 
because only one drug was the best in the large majority 
of patients. Of greater practical value might be our 
finding that amiloride seems similarly effective to 
spironolactone in the treatment of resistant hypertension. 
The efficacy and tolerability of amiloride when used in 
adequate doses are supported by our randomised 
comparison of amiloride 10–20 mg with hydro-
chlorothiazide 25–50 mg in PATHWAY-3.7 Although 
spironolactone was well tolerated over 12 weeks, 
gynaecomastia is a concern with longer-term treatment. 
Retrospective reports that its anti-androgen activity is 
associated with lower incidence of carcinoma of the 
prostate might persuade some patients to tolerate the 
gynaecomastia.33,34 Amiloride could now be considered an 
alternative for patients in whom spironolactone is not 
tolerated.
As for the increased awareness of primary aldosteronism 
as a potentially preventable or curable cause of resistant 
hypertension, possible investigations and treatments in 
selected centres and patients will probably vary greatly, as 
will what can be more widely recommended on the basis 
of available clinical and health economic evidence. 
Prospective evaluation of sodium-to-potassium ratios 
might allow their use as an initial screening filter. 
Management of primary aldosteronism is rapidly 
changing as less invasive modalities become available for 
diagnosis and treatment of functional adenomas.35
Our study has some limitations. By design, only some of 
the patients in PATHWAY-2 participated in the various 
substudies. However, baseline characteristics were similar 
between the cohorts. Prospective power was calculated for 
the primary outcome in PATHWAY-2, but not for the 
individual substudies, which were intended to allow 
prespecified, secondary mechanistic analyses that might 
help to explain the results of the main study. In our favour, 
the size of the study proved much larger than necessary to 
detect the primary outcome, having been powered to 
detect a difference of only 3 mm Hg between spirono-
lactone and other drugs, at an α of 0·003;3,6 indeed, post-
hoc analysis of the first cycle of treatment showed the 
superiority of spironolactone in just 80 patients.3 Urine 
aldosterone measurements might have helped to confirm 
a high prevalence of primary aldosteronism. Finally, the 
similarity and correlation of the amiloride responses 
with those previously measured on spironolactone add 
qualified support for use of open-label treatment to 
simplify and encourage complex rotation studies,6 but do 
not guarantee that the two potassium-sparing diuretics 
are interchangeable. The finding that only the spirono-
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lactone response correlated with SUSPPUP might point 
to spironolactone as the more effective drug when 
aldosterone is the cause of sodium retention, and 
amiloride when the cause is clearly downstream.
We conclude that the mineralocorticoid receptor 
antagonist spironolactone is an effective treatment of 
resistant hypertension because resistant hypertension is 
commonly a salt-retaining condition probably due to 
inappropriate aldosterone secretion. Amiloride seems to 
be an effective, well tolerated alternative to spironolactone. 
Finally, our findings should encourage debate about 
whether thresholds for diagnosis of primary aldo-
steronism should be reconsidered in patients presenting 
with resistant hypertension, and about the possibility of 
earlier diagnosis of primary aldosteronism to prevent 
development of resistant hypertension.
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